对MDM2-p53相互作用抑制剂 (2019-2023) 的最新专利审查 (2019-2023)
1Institute of Molecular and Industrial Biotechnology, Lodz University of Technology, Lodz, Poland.
Expert opinion on therapeutic patents
|October 22, 2024
概括
研究人员审查了针对MDM2-p53相互作用的抑制剂的近期专利 (2019-2023年),这是癌症的关键途径. 虽然没有药物进入市场,但几个有前途的化合物正在进行癌症治疗的临床试验.
科学领域:
- 在瘤学瘤学.
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
背景情况:
- 瘤抑制蛋白p53对于预防癌症至关重要,但通常被鼠标双分钟2 (MDM2) 或MDM4.
- 针对MDM2-p53相互作用为各种人类癌症提供了一个非基因毒性治疗策略.
研究的目的:
- 对2019-2023年期间关于MDM2-p53相互作用抑制剂的专利和专利申请进行审查.
- 将新型分子分类并评估其临床试验进展情况.
主要方法:
- 在Espacenet,谷歌专利和PubMed的综合文献搜索相关专利.
- 已识别的抑制剂分为五个结构类别的分类:单环,多环,螺旋-oxindole支架,衍生物和PROTACs.
- 对针对MDM2-p53通路的化合物的临床试验状态的分析.
主要成果:
- 该审查确定了MDM2-p53抑制剂的多种化学支架,包括新型单环,多环,螺旋氧,和基于PROTAC的化合物.
- 尽管自Nutlin-3发现以来进行了广泛的研究,但没有任何MDM2-p53抑制剂获得了市场批准.
- 超过10种化合物正在临床开发中,其中一些处于第三阶段试验,另一些获得FDA的孤儿药/快速通道指定.
结论:
- 关于MDM2-p53抑制剂的研究领域继续进步,目前正在对多种候选药物的临床评估.
- 尽管面临挑战,但这些抑制剂的开发对新型非遗传毒性抗癌疗法具有重大前景.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Covalently Linked Protein Regulators
6.8K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K


